Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer
Mathew, G. Mitchell, Andrew Down, J.M. Jacobs, L.A. Hamdy, F.C. Eaton, C. Rosario, D.J. Cross, S.S. Winder, S.J.
Mathew, G.
Mitchell, Andrew
Down, J.M.
Jacobs, L.A.
Hamdy, F.C.
Eaton, C.
Rosario, D.J.
Cross, S.S.
Winder, S.J.
Publication Date
2013
End of Embargo
Supervisor
Keywords
Rights
Peer-Reviewed
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Dystroglycan is frequently lost in adenocarcinoma, but the mechanisms and consequences are poorly understood. We report an analysis of beta-dystroglycan in prostate cancer in human tissue samples and in LNCaP cells in vitro. There is progressive loss of beta-dystroglycan immunoreactivity from basal and lateral surfaces of prostate epithelia which correlates significantly with increasing Gleason grade. In about half of matched bone metastases there is significant dystroglycan re-expression. In tumour tissue and in LNCaP cells there is also a tyrosine phosphorylation-dependent translocation of beta-dystroglycan to the nucleus. Analysis of gene expression data by microarray, reveals that nuclear targeting of beta-dystroglycan in LNCaP cells alters the transcription of relatively few genes, the most unregulated being the transcription factor ETV1. These data suggest that proteolysis, tyrosine phosphorylation and translocation of dystroglycan to the nucleus resulting in altered gene transcription could be important mechanisms in the progression of prostate cancer.
Version
No full-text in the repository
Citation
Mathew G, Mitchell A, Down JM et al (2013) Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer. Scientific Reports, 3. Article Number 2792.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article